Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
The epidermal growth factor receptor 2 (HER2) is a tyrosine kinase overexpressed in nearly 20% to 25% of invasive breast cancers. Trastuzumab is a humanized monoclonal antibody that targets HER2. The majority of patients with metastatic breast cancer initially respond to trastuzumab, however, within...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | International Journal of Breast Cancer |
| Online Access: | http://dx.doi.org/10.4061/2011/352182 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849411510286155776 |
|---|---|
| author | Gabriel L. Fiszman María A. Jasnis |
| author_facet | Gabriel L. Fiszman María A. Jasnis |
| author_sort | Gabriel L. Fiszman |
| collection | DOAJ |
| description | The epidermal growth factor receptor 2 (HER2) is a tyrosine kinase overexpressed in nearly 20% to 25% of invasive breast cancers. Trastuzumab is a humanized monoclonal antibody that targets HER2. The majority of patients with metastatic breast cancer initially respond to trastuzumab, however, within 1 year of treatment disease progresses. Several molecular mechanisms have been described as contributing to the development of trastuzumab resistance. They could be grouped as impaired access of trastuzumab to HER2, upregulation of HER2 downstream signaling pathways, signaling of alternative pathways, and impaired immune antitumor mechanisms. However, since many of them have overlapping effects, it would be of great clinical impact to identify the principal signaling pathways involved in drug resistance. Significant efforts are being applied to find other therapeutic modalities besides trastuzumab treatment to be used alone or in combination with current modalities. |
| format | Article |
| id | doaj-art-5df84d1599804d1ab40c36069f7aac39 |
| institution | Kabale University |
| issn | 2090-3189 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Breast Cancer |
| spelling | doaj-art-5df84d1599804d1ab40c36069f7aac392025-08-20T03:34:45ZengWileyInternational Journal of Breast Cancer2090-31892011-01-01201110.4061/2011/352182352182Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast CancerGabriel L. Fiszman0María A. Jasnis1Immunobiology Department, Institute of Oncology A. H. Roffo, University of Buenos Aires, Avenida San Martín 5481, CP1417 DTB Buenos Aires, ArgentinaImmunobiology Department, Institute of Oncology A. H. Roffo, University of Buenos Aires, Avenida San Martín 5481, CP1417 DTB Buenos Aires, ArgentinaThe epidermal growth factor receptor 2 (HER2) is a tyrosine kinase overexpressed in nearly 20% to 25% of invasive breast cancers. Trastuzumab is a humanized monoclonal antibody that targets HER2. The majority of patients with metastatic breast cancer initially respond to trastuzumab, however, within 1 year of treatment disease progresses. Several molecular mechanisms have been described as contributing to the development of trastuzumab resistance. They could be grouped as impaired access of trastuzumab to HER2, upregulation of HER2 downstream signaling pathways, signaling of alternative pathways, and impaired immune antitumor mechanisms. However, since many of them have overlapping effects, it would be of great clinical impact to identify the principal signaling pathways involved in drug resistance. Significant efforts are being applied to find other therapeutic modalities besides trastuzumab treatment to be used alone or in combination with current modalities.http://dx.doi.org/10.4061/2011/352182 |
| spellingShingle | Gabriel L. Fiszman María A. Jasnis Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer International Journal of Breast Cancer |
| title | Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer |
| title_full | Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer |
| title_fullStr | Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer |
| title_full_unstemmed | Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer |
| title_short | Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer |
| title_sort | molecular mechanisms of trastuzumab resistance in her2 overexpressing breast cancer |
| url | http://dx.doi.org/10.4061/2011/352182 |
| work_keys_str_mv | AT gabriellfiszman molecularmechanismsoftrastuzumabresistanceinher2overexpressingbreastcancer AT mariaajasnis molecularmechanismsoftrastuzumabresistanceinher2overexpressingbreastcancer |